| J9271 | Injection, pembrolizumab, 1 mg | 19,200 | $40 | $691.2K |
| J0897 | Injection, denosumab, 1 mg | 4,620 | $20 | $87.8K |
| 99214 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the… | 550 | $100 | $54.3K |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | 2,310 | $20 | $50.8K |
| J2506 | Injection, pegfilgrastim, excludes biosimilar, 0.5 mg | 580 | $80 | $43.2K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 350 | $100 | $35.2K |
| 99233 | The provider sees a patient for a subsequent hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 310 | $100 | $29.9K |
| 99223 | The provider sees a patient for an initial hospital inpatient or observation care visit involving evaluation and management (E/M). The visit involves a high level of medical decision making or the… | 160 | $130 | $20.9K |
| 99215 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the… | 130 | $140 | $18.8K |
| Q5106 | Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | 2,330 | $10 | $14K |